315 related articles for article (PubMed ID: 25793299)
1. Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
Kim JY; Shin E; Kim JW; Lee HS; Lee DW; Kim SH; Lee JO; Kim YJ; Kim JH; Bang SM; Ahn SH; Park DJ; Lee JS; Lee JS; Kim HH; Lee KW
PLoS One; 2015; 10(3):e0120324. PubMed ID: 25793299
[TBL] [Abstract][Full Text] [Related]
2. Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study).
Mori T; Ohue M; Takii Y; Hashizume T; Kato T; Kotake K; Sato T; Tango T
Oncol Rep; 2013 Feb; 29(2):437-44. PubMed ID: 23232805
[TBL] [Abstract][Full Text] [Related]
3. Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
Sasako M; Terashima M; Ichikawa W; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H
Gastric Cancer; 2015 Jul; 18(3):538-48. PubMed ID: 25112781
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral gene expression of 5-fluorouracil pharmacokinetics-related enzymes in stage I and II non-small cell lung cancer patients treated with uracil-tegafur after surgery: a prospective multi-institutional study in Japan.
Eguchi K; Oyama T; Tajima A; Abiko T; Sawafuji M; Horio H; Hashizume T; Matsutani N; Kato R; Nakayama M; Kawamura M; Kobayashi K
Lung Cancer; 2015 Jan; 87(1):53-8. PubMed ID: 25468199
[TBL] [Abstract][Full Text] [Related]
5. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
6. Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer.
Jeung HC; Rha SY; Shin SJ; Lim SJ; Roh JK; Noh SH; Chung HC
Anticancer Drugs; 2011 Sep; 22(8):801-10. PubMed ID: 21572321
[TBL] [Abstract][Full Text] [Related]
7. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1.
Ichikawa W; Takahashi T; Suto K; Shirota Y; Nihei Z; Shimizu M; Sasaki Y; Hirayama R
Int J Cancer; 2006 Oct; 119(8):1927-33. PubMed ID: 16736497
[TBL] [Abstract][Full Text] [Related]
8. [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
Sakurai Y; Kamoshida S; Furuta S; Sunagawa R; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1147-55. PubMed ID: 18633253
[TBL] [Abstract][Full Text] [Related]
9. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
[TBL] [Abstract][Full Text] [Related]
10. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.
Miyamoto S; Boku N; Ohtsu A; Yoshida S; Ochiai A; Okabe H; Fukushima M
Int J Oncol; 2000 Oct; 17(4):653-8. PubMed ID: 10995874
[TBL] [Abstract][Full Text] [Related]
12. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion.
Uchida K; Hayashi K; Kuramochi H; Takasaki K
Int J Oncol; 2001 Aug; 19(2):341-6. PubMed ID: 11445849
[TBL] [Abstract][Full Text] [Related]
13. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C
Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501
[TBL] [Abstract][Full Text] [Related]
14. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
Kuramochi H; Hayashi K; Uchida K; Nakajima G; Hatori T; Danenberg KD; Danenberg PV; Yamamoto M
Cancer Chemother Pharmacol; 2008 Dec; 63(1):85-9. PubMed ID: 18309485
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.
Kamoshida S; Shiogama K; Shimomura R; Inada K; Sakurai Y; Ochiai M; Matuoka H; Maeda K; Tsutsumi Y
Oncol Rep; 2005 Nov; 14(5):1223-30. PubMed ID: 16211289
[TBL] [Abstract][Full Text] [Related]
16. Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1.
Harada K; Kawashima Y; Yoshida H; Sato M
Oncol Rep; 2006 Jun; 15(6):1417-23. PubMed ID: 16685374
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
He MM; Zhang DS; Wang F; Wang ZX; Yuan SQ; Wang ZQ; Luo HY; Ren C; Qiu MZ; Jin Y; Wang DS; Chen DL; Zeng ZL; Li YH; He YY; Hao YT; Guo P; Wang FH; Zeng YX; Xu RH
Cancer Chemother Pharmacol; 2017 Jan; 79(1):69-79. PubMed ID: 27913881
[TBL] [Abstract][Full Text] [Related]
18. A quantitative evaluation of the determinant proteins for S-1 responsiveness in a biopsy specimen assists in patient selection to neoadjuvant therapy in cases of advanced gastric cancer.
Hashiguchi K; Kitajima Y; Kai K; Hiraki M; Nakamura J; Tokunaga O; Noshiro H; Miyazaki K
Int J Oncol; 2010 Aug; 37(2):257-64. PubMed ID: 20596652
[TBL] [Abstract][Full Text] [Related]
19. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
20. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
